Root Bidco S.a.r.l. -- Moody's assigns B2 to Root Bidco, TLB, RCF; negative outlook

In This Article:

Rating Action: Moody's assigns B2 to Root Bidco, TLB, RCF; negative outlook

Global Credit Research - 07 Aug 2020

Frankfurt am Main, August 07, 2020 -- Moody's Investors Service, ("Moody's") today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating to Root Bidco S.a.r.l. (Root Bidco or Rovensa) and B2 instrument ratings to the senior secured E440 million term loan B (TLB) and the E115 million revolving credit facility (RCF). The outlook is negative. Moody's expects to withdraw all ratings for EUROPEAN CROPS PRODUCTS 2 S.A.R.L. once the transaction closes in late 2020.

RATINGS RATIONALE

Rovensa's B2 CFR reflects the modest scale with annual revenues of E364 million and geographical concentration on the Iberian peninsula where 39% of fiscal year 2020 revenues were generated (FY16: 53%). The company since 2016 has grown from a revenue base of E225 million organically and through acquisitions. In line with the previous M&A track record Moody's assumes that Rovensa remains acquisitive, however the current capital structure leaves limited headroom for debt-funded acquisitions. Likely earn-outs for past acquisitions are viewed as a debt adjustment and are expected to be around E9.2 million at financial close of the transaction. The amount will tail off over time. The continued international expansion of the company, with a focus on existing geographies, including Western and Central Europe, the Americas and the APAC and MENA regions, will further lower the geographical exposure to the Iberian peninsula. The increased regional diversification into markets that Rovensa already knows should reduce volatility from adverse weather events that may have a negative impact on demand for Rovensa's products.

Rovensa has a broad and diversified portfolio of products across specialty crop nutrition (SCN), off-patent crop protection (CP) and biological crop protection (BCP). SCN is R&D-intensive, supported by 40 researchers, fast-growing and has an EBITDA margin in the 25%-30% range. CP has an EBITDA margin of around 20%. This is lower than that of its multinational peers Bayer AG (Baa1 stable), Syngenta AG (Ba2 stable) and E.I. du Pont de Nemours and Company (A3 stable) whose R&D expenditure is higher given their focus on patent products, where Rovensa is focused on post-patent products only, which have lower margins but require lower R&D expenditure. Rovensa has built a significant business in BCP through M&A. BCP product demand is expected to lead to higher than market growth, benefitting from positive environmental and dietary trends. This division generates EBITDA margins in the 25-30% range. Rovensa benefits from entrenched domestic leadership positions across its portfolio.